Filing Details Polaryx Therapeutics, Inc. (NASDAQ:PLYX) filed a definitive proxy statement (DEF 14A) with the Securities and Exchange Commission on July 28, 2026. The company's…
Polaryx Therapeutics, Inc. (NASDAQ:PLYX) filed a definitive proxy statement (DEF 14A) with the Securities and Exchange Commission on July 28, 2026.
The company's proxy statement provides information for shareholders ahead of the annual meeting, including board nominations, executive compensation, and proposals for shareholder vote.
Polaryx Therapeutics, Inc.'s stock currently trades at $1.99.
SEC filings provide mandatory disclosures that give investors access to the same material information available to institutional investors. Reviewing Polaryx Therapeutics, Inc.'s filings alongside price action and analyst commentary provides a more complete picture of the company's current situation.
All SEC filings for Polaryx Therapeutics, Inc. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View PLYX Stock Page
Browse all filings on our PLYX SEC filings page.
Public companies like Polaryx Therapeutics, Inc. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.
Current market data
NASDAQ · PLYX
$2.00
Up: +$0.01 · +0.50%
Live quote updated
Keep reading
